Comparative Pharmacology
Head-to-head clinical analysis: BENADRYL PRESERVATIVE FREE versus MYMETHAZINE FORTIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENADRYL PRESERVATIVE FREE versus MYMETHAZINE FORTIS.
BENADRYL PRESERVATIVE FREE vs MYMETHAZINE FORTIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diphenhydramine competitively antagonizes histamine at H1-receptors on effector cells, leading to relief of allergic symptoms. It also possesses anticholinergic, antiemetic, sedative, and local anesthetic effects.
Mymethazine fortis is a phenothiazine derivative that exerts antipsychotic and antiemetic effects primarily by blocking postsynaptic dopamine D2 receptors in the mesolimbic system, as well as possessing anticholinergic, antihistaminergic, and alpha-adrenergic antagonistic properties.
25-50 mg IV/IM every 4-6 hours as needed; maximum single dose 100 mg, maximum daily dose 400 mg.
50 mg orally every 6 hours as needed for nausea and vomiting.
None Documented
None Documented
Terminal elimination half-life: 4-8 hours (mean ~5 hours). Prolonged in hepatic impairment (up to 2-fold) and elderly (7-12 hours).
Terminal elimination half-life is 15-20 hours; in renal impairment (CrCl <30 mL/min), may extend to 30-40 hours, requiring dose adjustment.
Primarily renal (90% as metabolites and unchanged drug); ~1% excreted in feces via bile. Unchanged diphenhydramine accounts for <5% of urinary recovery.
Primarily renal (70-80% as unchanged drug and metabolites, with about 30% as unchanged); fecal (10-15%) via biliary elimination.
Category C
Category C
Antihistamine
Antihistamine/Decongestant Combination